Chimerix prices upsized IPO at $14 midpoint

By
A A A

Chimerix, which is developing a potent antiviral drug for use in stem cell transplants, raised $102 million by offering 7.3 million shares at $14, within the range of $13 to $15. The company had originally planned to sell 6.1 million shares before upsizing the deal by 20%. Aisling Capital agreed to purchase $15 million of shares on the IPO (15% of the deal). Chimerix plans to list on the NASDAQ under the symbol CMRX. Morgan Stanley and Cowen & Company acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CMRX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

40,230,408
  • $15.525 ▲ 0.03%
31,383,802
  • $2.56 ▲ 15.84%
29,532,497
  • $94.445 ▲ 0.54%
29,320,042
  • $69.20 ▼ 0.29%
26,540,037
  • $7.255 ▲ 2.33%
26,113,035
  • $34.66 ▲ 1.76%
25,178,931
  • $3.84 ▲ 1.59%
24,129,823
  • $44.84 ▲ 0.01%
As of 7/22/2014, 02:12 PM